Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,440 across all filing types
Latest filing 2023-04-26 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '嘉事堂药业股份有限公司2023 年第一季度报告' which translates to 'Jia Shi Tang Pharmaceutical Co., Ltd. 2023 First Quarter Report'. It contains detailed financial data including balance sheets, income statements, cash flow statements, and shareholder information for the first quarter of 2023. The document explicitly states it is a quarterly report and mentions that it is unaudited. The length of the document (over 11,000 characters) and the presence of comprehensive financial statements confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-04-26 Chinese
2022年关于计提商誉减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the company Jia Shi Tang Pharmaceutical Co., Ltd. regarding the impairment provision for goodwill related to a subsidiary. It details the background of the goodwill, the impairment testing process, the amount of impairment recognized, and the impact on the company's financials for the year 2022. It includes opinions from the audit committee, board of directors, independent directors, and supervisory board, confirming the appropriateness of the impairment. The document is a formal disclosure of an accounting estimate adjustment (goodwill impairment) and its financial impact, but it is not a full annual report or audit report. It is a regulatory announcement about a specific accounting event affecting financial statements, typically classified as a Regulatory Filing (RNS) because it does not contain full financial statements or comprehensive financial analysis, nor is it a standalone audit report or annual report. The document length is under 5,000 characters and is a detailed announcement rather than a report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2023-04-20 Chinese
2022年年度审计报告
Annual Report Classification · 100% confidence The document is a comprehensive financial report for 嘉事堂药业股份有限公司 covering the fiscal year 2022. It includes an audit report by a registered accounting firm (安永华明), detailed financial statements such as consolidated balance sheets, income statements, cash flow statements, and notes to the financial statements. The audit report contains the auditor's opinion, basis for opinion, key audit matters, responsibilities of management and auditors, and signatures of certified public accountants. The presence of full financial statements and detailed audit information indicates this is the official annual report covering the company's full financial performance for the year. The document length (15,000 characters) and content confirm it is not merely an announcement or certification but the full report itself. Therefore, the appropriate classification is Annual Report (10-K).
2023-04-20 Chinese
独立董事对担保等事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various matters discussed at the company's seventh board of directors' second meeting. It includes opinions on related party transactions, internal control self-assessment, profit distribution plan, expected related party transactions for the next year, goodwill impairment testing, and risk preference statement for 2022. The document is a formal statement of independent directors' views and approvals related to board meeting agenda items, not a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis. It is not a report publication announcement or a certification letter but a governance-related document reflecting board oversight and compliance with regulatory requirements. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions from the board or senior management.
2023-04-20 Chinese
2023年度风险偏好陈述书
Regulatory Filings Classification · 95% confidence The document is titled as a "2023年度风险偏好陈述书" which translates to "2023 Annual Risk Appetite Statement". It details the company's risk appetite, qualitative and quantitative risk indicators, and risk limits for the year 2023. The content focuses on risk management policies, risk tolerance levels, and monitoring frequencies. There are no financial statements, earnings data, or regulatory certifications present. The document is a formal statement on risk preferences and management rather than a financial report or announcement. It is not a report publication announcement since it contains substantive content rather than just a notice. The document fits best under the category of Regulatory Filings (RNS) as it is a compliance-related disclosure about risk management and does not fit other specific categories like Annual Report, Interim Report, or Audit Report.
2023-04-20 Chinese
关于向银行申请2023年综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's application for a comprehensive credit facility (授信额度) from banks, including details about the credit limit, authorization, and the need for shareholder approval. It does not contain financial statements or detailed financial performance data. It is an update on financing activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear content focus on financing.
2023-04-20 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.